NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Depomed, Inc. (NASDAQ: DEPO) resulting from allegations that Depomed may have issued materially misleading business information to the investing public.
On August 7, 2017, during aftermarket hours, Depomed announced that it had received a request for information relating to the promotion of opioids from the U.S. Senate Committee on Homeland Security and Governmental Affairs, as well as from the Office of the Attorney General of Maryland and the U.S. Department of Justice. On this news, shares of Depomed fell sharply during intraday trading on August 8, 2017.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Depomed investors. If you purchased shares of Depomed on or before August 7, 2017, please visit the firm’s website at http://www.rosenlegal.com/cases-1185.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.